Head-to-head · Stock vs Stock
Pfizer vs Merck & Co.
PFE vs MRK: the verdict
How PFE and MRK compare today, and what CleaRank Financial AI makes of it.
The verdict
Price, side by side
Both prices start at 0% on the first day of the period you pick, so the moves compare directly.
Rebased price
Over 1 year: PFE gained 19.8% and MRK gained 70.7%, a gap of 50.8 points in MRK's favour.
Valuation and profitability
What each costs relative to its earnings and sales, and how much of its revenue it keeps.
Side by side
Valuation
Lower multiples mean you pay less for each dollar of earnings or sales.
Profitability
How much of each dollar of revenue becomes profit, and how hard the capital works.
Earnings reality check
PFE
No reliable earnings figures in our data.
MRK
MRK beat the estimate in 8 of its last 8 reports (latest Oct '26); the shares fell in the first session after 3 of those beats.
Momentum and sentiment
The indicators behind each AI score, side by side.
Indicators side by side
Risk and practical tips
How much each moves, how much return each has paid for that risk, and what to watch if you hold either.
Risk measures
- For PFE, watch the 20-day EMA at $29.62 above the price and the 50-day SMA at $28.77 below it.
- For MRK, watch the 52-week high at $156.92 above the price and the 20-day EMA at $146.50 below it.
PFE vs MRK: long-term scenarios
Simulated paths from each price history. A range of outcomes, not a forecast.
Simulated growth of $10,000
In the median simulated path, $10,000 in PFE grows to about $12,700 and $10,000 in MRK grows to about $19,200 by 2035. The paths come from each asset's own volatility and capped historical trend; they are statistical outcomes, not forecasts.
PFE vs MRK: questions people ask
Answered from the figures on this page.